Short-term effect of combined therapy with Jinlong capsule and transcatheter arterial chemoembolization on patients with primary hepatic carcinoma and its influence on serum osteopontin expression

Chinese Journal of Integrative Medicine

Volumn 16, Issue 2, 2010, Pages 109-113

  Wu, Guo Lin ^a   Zhang, Li ^b   Li, Tian Yi ^c   Chen, Jiu ^a   Yu, Guo You ^a   Li, Jian Ping ^a  

^a ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b Center for Drug Reevaluation State Food and Drug Administration   (China)

^c ZHEJIANG CHINESE MEDICAL UNIVERSITY   (China)

Author keywords

Clinical efficacy; Jinlong capsule; Osteopontin; Primary hepatic carcinoma; Transcatheter arterial chemoembolization

Indexed keywords

10 HYDROXYCAMPTOTHECIN; DEXAMETHASONE; JINLONG; OSTEOPONTIN; OXALIPLATIN; PIRARUBICIN; PLANT MEDICINAL PRODUCT; UNCLASSIFIED DRUG;

ARTICLE; CANCER PATIENT; CHEMOEMBOLIZATION; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG EFFECT; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIMARY HEPATIC CARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL;

ADULT; AGED; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CAPSULES; CARCINOMA, HEPATOCELLULAR; CATHETERIZATION, PERIPHERAL; CHEMOEMBOLIZATION, THERAPEUTIC; COMBINED MODALITY THERAPY; DRUGS, CHINESE HERBAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; LIVER; LIVER NEOPLASMS; MALE; MIDDLE AGED; OSTEOPONTIN; TIME FACTORS; TREATMENT OUTCOME;

EID: 77954504936     PISSN: 16720415     EISSN: 19930402     Source Type: Journal    
DOI: 10.1007/s11655-010-0109-9     Document Type: Article

References (10)

1. The Hepatoma Board of Chinese Anti-cancer Association. The clinical diagnosis and standard of staging of primary hepatic carcinoma. Chin J Hepatol (Chin) 2001;9:324-325.
2. Sun Y, ed. Medical oncology. Beijing: People's Medical Publishing House, 2001:995-996.
3. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 2000;92:205-216. (Pubitemid 30099779)
4. Liu YY, Lai JX. The progress of hepatoma treatment. J Clin Surg (Chin) 2007;15:2-7.
5. Poon RT, Fan ST, Tsang FH, Wong J. Locoregional therapies for hepatocellular carcinoma: a critical review from the surgeon's perspective. Ann Surg 2002; 235:466-486. (Pubitemid 34258345)
6. Su XK, Zhou WS, Xu FB, Wang FJ, Zhao TQ, Lin YS, et al. The clinical observation of combination treatment of traditional Chinese medcine and TACE of primary hepatic carcinoma in 219 patients. J Tradit Chin Med (Chin) 2004; 45:434-436.
7. Senger DR, Perruzzi CA. Secreted phosphoprotein markers for neoplastic transformation of human epithelial and fibroblastic cells . Cancer Res 1985;45:5818-5823.
8. Coppola D, Szabo M, Boulware D, Muraca P, Alsarraj M, Chambers AF, et al. Correlation of osteopontin protein. Clin Cancer Res 2004;10:184-190.
9. Gotoh M, Sakamoto M, Kanetaka K, Chuuma M, Hirohashi S. Overexpression of osteopontin in hepatocellular carcinoma. Pathol Int 2002;52:19-24.
10. Ye QH, Qin LX, Forgues M, He P, Kim JW, Peng AC, et al. Predicting hepatitis B virus-positive metastatic hepatocellular carcinomas using gene expression profiling and supervised machine learning. Nat Med 2003;9:416-423. (Pubitemid 36460075)